Payment overview · 2025
General Payments
$655.97
39 reported records · 13 companies
Healthcare provider profile · identity verified
Alisha J Cooley, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SOMERSET, KY · NPI 1851699060
Verified facts
What the public records show
CMS Open Payments records show Alisha J Cooley, APRN received $655.97 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 56.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $367.95 | 56.1% | 23 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.06 | 7.5% | 3 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $39.95 | 6.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.36 | 5.8% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $36.45 | 5.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.43 | 3.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.77 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.17 | 2.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.89 | 2.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.89 | 2.3% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.63 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.78 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3.64 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $655.97 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $161.90 | 8 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $161.90 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.40 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $102.00 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.65 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.06 | 3 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $39.95 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $39.95 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.36 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $3.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 599 | 92 |
| Omeprazole | Omeprazole | 499 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 60 |
| Lisinopril | Lisinopril | 250 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 44 |
| Montelukast Sodium | Montelukast Sodium | 186 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 35 |
| Sertraline Hcl | Sertraline Hcl | 150 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 49 |
| Furosemide | Furosemide | 145 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 41 |
| Eliquis | Apixaban | 131 | 18 |
| Gabapentin | Gabapentin | 130 | 45 |
| Metformin Hcl | Metformin Hcl | 130 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 39 |
| Famotidine | Famotidine | 118 | 24 |
| Potassium Chloride | Potassium Chloride | 115 | 31 |
| Lorazepam | Lorazepam | 113 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 24 |
| Ozempic | Semaglutide | 103 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 20 |
| Simvastatin | Simvastatin | 91 | 15 |
| Farxiga | Dapagliflozin Propanediol | 86 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 82 | 13 |
| Trazodone Hcl | Trazodone Hcl | 81 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 16 |
| Linzess | Linaclotide | 75 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | suppressed |
| Allopurinol | Allopurinol | 65 | suppressed |
| Celecoxib | Celecoxib | 64 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 64 | 15 |
| Tramadol Hcl | Tramadol Hcl | 63 | 17 |
| Promethazine Hcl | Promethazine Hcl | 62 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | suppressed |
| Clonazepam | Clonazepam | 57 | 17 |
| Vascepa | Icosapent Ethyl | 56 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 13 |
| Ibuprofen | Ibuprofen | 54 | 28 |
| Risperidone | Risperidone | 53 | 14 |
| Mounjaro | Tirzepatide | 50 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 26 |
| Propranolol Hcl | Propranolol Hcl | 50 | 11 |
| Azithromycin | Azithromycin | 49 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 42 |
| Bupropion Xl | Bupropion Hcl | 48 | 13 |
| Meloxicam | Meloxicam | 47 | 20 |
| Desmopressin Acetate | Desmopressin Acetate | 45 | suppressed |
| Losartan Potassium | Losartan Potassium | 45 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Gemfibrozil | Gemfibrozil | 43 | 12 |
| Fluconazole | Fluconazole | 41 | 31 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Ranolazine Er | Ranolazine | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 13 |
| Alprazolam | Alprazolam | 40 | 13 |
| Buspirone Hcl | Buspirone Hcl | 40 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | 13 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 31 |
| Levofloxacin | Levofloxacin | 35 | 25 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Nystatin | Nystatin | 29 | 13 |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Mupirocin | Mupirocin | 28 | 26 |
| Prednisone | Prednisone | 28 | 21 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 19 |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 21 |
| Glipizide | Glipizide | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 23 | 17 |
| Olanzapine | Olanzapine | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Elinest | Norgestrel-Ethinyl Estradiol | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Kariva | Desog-E.Estradiol/E.Estradiol | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $655.97 · 39 records | ABBVIE INC. | ARISTADA, CAPLYTA, ENTYVIO, FANAPT, IQIRVO, LEQVIO, LYBALVI, MOUNJARO, NURTEC ODT, Natroba, QULIPTA, REXULTI, RINVOQ, SKYRIZI, Spinosad, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error